Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant. Issue 2 (17th February 2022)

• Record Type: Journal Article
• Authors: Jullien, Maxime; Coste‐Burel, Marianne; Clemenceau, Beatrice; Letailleur, Valentin; Guillaume, Thierry; Peterlin, Pierre; Garnier, Alice; Bourgeois, Amandine Le; Imbert, Berthe‐Marie; Ollier, Jocelyn; Grain, Audrey; Touzeau, Cyrille; Moreau, Philippe; Béné, Marie C; Vié, Henri; Chevallier, Patrice
• Is Part Of: EJHaem. Volume 3:Issue 2(2022)
• Page Start: 484
• Page End: 487
• Publication Date: 2022-02-17
• Subjects: allogeneic -- cellular response -- COVID‐19 -- hematological -- humoral response -- SARS‐CoV‐2 mRNA -- vaccine; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.398
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: The impact of pre‐transplant anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo‐HSCT) and/or their donors is reported here, showing that the persistence of anti‐SARS‐CoV‐2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti‐SARS‐CoV‐2 spike glycoprotein CD3+ T‐cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti‐SARS‐CoV‐2 vaccination of both recipients and donors before Allo‐HSCT.